Opus Genetics (IRD) EBITDA (2010 - 2026)
Opus Genetics (IRD) reported EBITDA of -$65.5 million for Q1 2026, down 699.79% year-over-year from $10.9 million in Q1 2025, and down 296.63% on a QoQ basis from -$16.5 million in Q4 2025.
Opus Genetics (IRD) has 17 years of EBITDA data on file, last reported at -$65.5 million in Q1 2026.
- Quarterly EBITDA fell 699.79% year-over-year to -$65.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$106.9 million (down 82.42% YoY) and the FY2025 annual result came in at -$49.6 million, up 13.8% from the prior year.
- EBITDA fell to -$65.5 million in Q1 2026 per IRD's latest filing, from -$16.5 million in the prior quarter.
- Across five years, EBITDA topped out at $33.9 million in Q4 2022 and bottomed at -$65.5 million in Q1 2026.
- The 5-year median for EBITDA is -$7.1 million (2024), against an average of -$9.7 million.
- The widest annual swing landed in 2022, when EBITDA soared 637.64%; it then slumped 699.79% in 2026.
- Tracing IRD's EBITDA over 5 years: stood at $33.9 million in 2022, then tumbled by 114.13% to -$4.8 million in 2023, then tumbled by 632.74% to -$35.1 million in 2024, then surged by 52.97% to -$16.5 million in 2025, then tumbled by 296.63% to -$65.5 million in 2026.
- Per Business Quant, the three latest IRD EBITDA figures stand at -$65.5 million (Q1 2026), -$16.5 million (Q4 2025), and -$17.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 661.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 201.19 Mn |
| 10 | Opus Genetics | 357.99 Mn | 298.03 Mn | - | -65.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -65.54 Mn |
| Dec 31, 2025 | -16.52 Mn |
| Sep 30, 2025 | -17.45 Mn |
| Jun 30, 2025 | -7.42 Mn |
| Mar 31, 2025 | -8.19 Mn |
| Dec 31, 2024 | -35.14 Mn |
| Sep 30, 2024 | -7.53 Mn |
| Jun 30, 2024 | -7.77 Mn |
| Mar 31, 2024 | -7.11 Mn |
| Dec 31, 2023 | -4.80 Mn |
| Sep 30, 2023 | 5.56 Mn |
| Jun 30, 2023 | -4.96 Mn |
| Mar 31, 2023 | -5.79 Mn |
| Dec 31, 2022 | 33.94 Mn |
| Sep 30, 2022 | -4.53 Mn |
| Jun 30, 2022 | -4.93 Mn |
| Mar 31, 2022 | -6.60 Mn |
| Dec 31, 2021 | -6.31 Mn |
| Sep 30, 2021 | -4.23 Mn |
| Jun 30, 2021 | -7.14 Mn |
| Mar 31, 2021 | -39.01 Mn |
| Dec 31, 2020 | -18.68 Mn |
| Sep 30, 2020 | -1.25 Mn |
| Jun 30, 2020 | -1.60 Mn |
| Mar 31, 2020 | -3.09 Mn |
| Dec 31, 2019 | 5.01 Mn |
| Sep 30, 2019 | -2.28 Mn |
| Jun 30, 2019 | -2.99 Mn |
| Mar 31, 2019 | -3.94 Mn |
| Dec 31, 2018 | -4.97 Mn |
| Sep 30, 2018 | -4.68 Mn |
| Jun 30, 2018 | -5.00 Mn |
| Mar 31, 2018 | -5.89 Mn |
| Dec 31, 2017 | -4.90 Mn |
| Sep 30, 2017 | -4.22 Mn |
| Jun 30, 2017 | -4.28 Mn |
| Mar 31, 2017 | -3.95 Mn |
| Dec 31, 2016 | -3.92 Mn |
| Sep 30, 2016 | -3.72 Mn |
| Jun 30, 2016 | -3.91 Mn |
| Mar 31, 2016 | -4.86 Mn |
| Dec 31, 2015 | -4.37 Mn |
| Sep 30, 2015 | -4.66 Mn |
| Jun 30, 2015 | -4.82 Mn |
| Mar 31, 2015 | -4.42 Mn |
| Dec 31, 2014 | -3.85 Mn |
| Sep 30, 2014 | -3.14 Mn |
| Jun 30, 2014 | -3.50 Mn |
| Mar 31, 2014 | -2.76 Mn |
| Dec 31, 2013 | -2.32 Mn |
| Sep 30, 2013 | -1.81 Mn |
| Jun 30, 2013 | -1.90 Mn |
| Mar 31, 2013 | -1.90 Mn |
| Dec 31, 2012 | -1.04 Mn |
| Sep 30, 2012 | -1.79 Mn |
| Jun 30, 2012 | -1.84 Mn |
| Mar 31, 2012 | -1.87 Mn |
| Dec 31, 2011 | -2.39 Mn |
| Sep 30, 2011 | -3.34 Mn |
| Jun 30, 2011 | -6.45 Mn |
| Mar 31, 2011 | -3.91 Mn |
| Dec 31, 2010 | -3.16 Mn |
| Sep 30, 2010 | -2.37 Mn |
| Jun 30, 2010 | -3.19 Mn |